Association of the adipokine Chemerin with the development and progression of liver fibrosis

Xinyuan ZHANG; Nuoqi ZHANG; Guohui YU; Wenshuai REN; Yaling WANG

doi:10.12449/JCH250125

Volume 41 Issue 1

Jan. 2025

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2025 > 41(1): 164-169

PDF( 950 KB)

Association of the adipokine Chemerin with the development and progression of liver fibrosis

DOI: 10.12449/JCH250125

1.
School of Basic Medical Sciences，Hebei Medical University，Shijiazhuang 050000，China
2.
Department of Cardiology，The Second Hospital of Hebei Medical University，Shijiazhuang 050000，China

Research funding:

Nature Science Foundation of Hebei Province (H2021206141);

Hebei Medical University Undergraduate Innovative Experimental Project (USIP2022119)

More Information

Corresponding author: WANG Yaling， wangyaling81@163.com （ORCID： 0000-0002-9829-1744）
Received Date: 2024-04-14
Accepted Date: 2024-05-28
Published Date: 2025-01-25

Abstract

Abstract

Liver fibrosis is the common pathological process in the progression of various chronic liver diseases to liver cirrhosis， and it greatly affects the prognosis of patients with chronic liver diseases. As a novel adipokine， Chemerin participates in the metabolism of glucose and lipids and inflammation， and various studies have shown that the expression level of Chemerin is correlated with the degree of liver fibrosis， suggesting that Chemerin may be involved in the process of liver fibrosis by regulating metabolism and inflammation. Chemerin has shown certain potential in the auxiliary diagnosis of liver fibrosis and the intervention against the progression of liver fibrosis. This article reviews the potential role and mechanism of action of Chemerin in the process of liver fibrosis， in order to provide new ideas for the diagnosis and treatment of liver fibrosis.
- Hepatic Fibrosis,
- Adipokines,
- Chemerin

FullText(HTML)

References(43)

References

[1]	CHEN ZW, SUN H. Nrf2: A new target for nonalcoholic fatty liver disease[J]. Acta Pharm Sin, 2022, 57( 11): 3268- 3275. DOI: 10.16438/j.0513-4870.2022-0561. 陈智伟, 孙华. Nrf2: 非酒精性脂肪性肝病的新靶点[J]. 药学学报, 2022, 57( 11): 3268- 3275. DOI: 10.16438/j.0513-4870.2022-0561.
[2]	ESLAM M, SANYAL AJ, GEORGE J, et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020, 158( 7): 1999- 2014. DOI: 10.1053/j.gastro.2019.11.312.
[3]	REN Q, WANG HY, ZENG Y, et al. Circulating chemerin levels in metabolic-associated fatty liver disease: A systematic review and meta-analysis[J]. Lipids Health Dis, 2022, 21( 1): 27. DOI: 10.1186/s12944-022-01637-7.
[4]	ZHU XJ, QIU H, LIU SL, et al. Research progress of Chemerin in polycystic ovary syndrome[J]. Acta Physiol Sin, 2024, 76( 3): 429- 437. DOI: 10.13294/j.aps.2024.0001. 朱晓娟, 邱杭, 刘圣兰, 等. Chemerin在多囊卵巢综合征中的研究进展[J]. 生理学报, 2024, 76( 3): 429- 437. DOI: 10.13294/j.aps.2024.0001.
[5]	QIU H, ZHU XJ, TONG TT, et al. Research progress of Chemerin protein and related diseases[J]. J Med Res Combat Trauma Care, 2023, 36( 6): 638- 643. DOI: 10.16571/j.cnki.2097-2768.2023.06.016. 邱杭, 朱晓娟, 佟天天, 等. Chemerin蛋白与相关疾病研究进展[J]. 医学研究与战创伤救治, 2023, 36( 6): 638- 643. DOI: 10.16571/j.cnki.2097-2768.2023.06.016.
[6]	WANG W, ZHANG J, PU C. Expression of Visfatin and Chemerin in serum, umbilical blood and placenta of patients with gestational diabetes mellitus and the mechanism of insulin resistance[J]. J Mod Lab Med, 2022, 37( 1): 21- 27. DOI: 10.3969/j.issn.1671-7414.2022.01.005. 王伟, 张静, 浦春. 妊娠糖尿病患者血清、脐血及胎盘组织中Visfatin和Chemerin的表达与胰岛素抵抗发生机制的研究[J]. 现代检验医学杂志, 2022, 37( 1): 21- 27. DOI: 10.3969/j.issn.1671-7414.2022.01.005.
[7]	BAI XL, CHEN F, ZHANG LR, et al. Research progress of Chemerin in nervous system diseases[J]. J Neurosci Ment Health, 2024, 24( 2): 127- 132. 柏晓林, 陈凤, 张力壬, 等. Chemerin在神经系统疾病中的研究进展[J]. 神经疾病与精神卫生, 2024, 24( 2): 127- 132.
[8]	ZHAO MY, LI YM, LIU HY, et al. Research progress of insulin resistance markers in atherogenesis[J]. Basic Clin Med, 2022, 42( 8): 1302- 1305. DOI: 10.16352/j.issn.1001-6325.2022.08.1302. 赵茂宇, 李佑美, 刘焕云, 等. 胰岛素抵抗标志物在动脉粥样硬化发病中的研究进展[J]. 基础医学与临床, 2022, 42( 8): 1302- 1305. DOI: 10.16352/j.issn.1001-6325.2022.08.1302.
[9]	HELFER G, WU QF. Chemerin: A multifaceted adipokine involved in metabolic disorders[J]. J Endocrinol, 2018, 238( 2): R79- R94. DOI: 10.1530/JOE-18-0174.
[10]	XU ZJ, CHEN XB, CAI BJ, et al. Research progress in the relationship between all-trans retinoic acid and liver diseases and the associated molecular mechanisms[J]. Chin J Gen Surg, 2021, 30( 7): 858- 865. DOI: 10.7659/j.issn.1005-6947.2021.07.012. 许召君, 陈小彬, 才保加, 等. 全反式维甲酸与肝脏疾病的关系及其分子机制研究进展[J]. 中国普通外科杂志, 2021, 30( 7): 858- 865. DOI: 10.7659/j.issn.1005-6947.2021.07.012.
[11]	ZHAO XA. Curcumin inhibits hepatic fibrosis by inhibiting monocyte infiltration and reducing monocyte-derived GRN secretion[D]. Nanjing: Nanjing University of Chinese Medicine, 2019. 赵祥安. 姜黄素抑制单核细胞浸润并减少单核细胞来源GRN分泌抗肝纤维化的机制研究[D]. 南京: 南京中医药大学, 2019.
[12]	NIU YY, FAN ZK, WANG LD, et al. Research progress on induced hepatic stellate cell ferroptosis in prevention and treatment of liver fibrosis[J]. China J Chin Mater Med, 2024, 49( 9): 2281- 2289. DOI: 10.19540/j.cnki.cjcmm.20240208.601. 牛媛媛, 樊泽坤, 汪龙德, 等. 诱导肝星状细胞铁死亡在肝纤维化防治中的研究进展[J]. 中国中药杂志, 2024, 49( 9): 2281- 2289. DOI: 10.19540/j.cnki.cjcmm.20240208.601.
[13]	QIN LJ, ZHANG L, HOU P, et al. Research progress in pathogenesis of liver fibrosis[J]. J Jilin Med Univ, 2021, 42( 5): 369- 371. DOI: 10.13845/j.cnki.issn1673-2995.2021.05.019. 秦利静, 张露, 侯鹏, 等. 肝纤维化发病机制的研究进展[J]. 吉林医药学院学报, 2021, 42( 5): 369- 371. DOI: 10.13845/j.cnki.issn1673-2995.2021.05.019.
[14]	HAO SD, LIU CP, LI YT, et al. Research progress of hepatic stellate cell activation-related signal pathways in liver fibrosis[J]. Chin J Gastroenterol Hepatol, 2022, 31( 2): 131- 135. DOI: 10.3969/j.issn.1006-5709.2022.02.003. 郝少东, 刘彩萍, 李月廷, 等. 肝星状细胞活化相关信号通路在肝纤维化中的研究进展[J]. 胃肠病学和肝病学杂志, 2022, 31( 2): 131- 135. DOI: 10.3969/j.issn.1006-5709.2022.02.003.
[15]	YI YF, CHEN CL. Study of serum chemerin and hs-CRP in patients with nonalcoholic fatty liver disease complicating insulin resistance[J]. Chongqing Med, 2017, 46( 2): 172- 174. DOI: 10.3969/j.issn.1671-8348.2017.02.008. 易玉芳, 陈春莲. 非酒精性脂肪肝病合并胰岛素抵抗患者血清chemerin和hs-CRP水平的研究[J]. 重庆医学, 2017, 46( 2): 172- 174. DOI: 10.3969/j.issn.1671-8348.2017.02.008.
[16]	WANG YJ, LI LX. Mechanisms of adipokines regulating inflammation in non-alcoholic fatty liver disease[J]. Med Recapitul, 2022, 28( 13): 2516- 2522. DOI: 10.3969/j.issn.1006-2084.2022.13.004. 王羽洁, 李连喜. 调控炎症的脂肪因子在非酒精性脂肪性肝病中的作用机制[J]. 医学综述, 2022, 28( 13): 2516- 2522. DOI: 10.3969/j.issn.1006-2084.2022.13.004.
[17]	LI ZY, LIANG XM, LI X, et al. Expression of serine protease inhibitors, endothelins and chemerin in T2DM patients with NAFLD and analysis of their relationship with insulin resistance[J]. Anhui Med Pharm J, 2021, 25( 11): 2265- 2269. DOI: 10.3969/j.issn.1009-6469.2021.11.033. 李曾一, 梁新明, 李星, 等. 血清丝氨酸蛋白酶抑制剂、内脂素、趋化素在2型糖尿病并发非酒精性脂肪性肝病中的表达及与胰岛素抵抗的关系[J]. 安徽医药, 2021, 25( 11): 2265- 2269. DOI: 10.3969/j.issn.1009-6469.2021.11.033.
[18]	QIANG HM, TANG JW, ZHAO R, et al. Effect of the adjuvant Baogan Jiangzhi decoction therapy on liver function and insulin sensitivity in patients with nonalcoholic fatty liver disease[J]. J Hainan Med Univ, 2018, 24( 6): 707- 710. DOI: 10.13210/j.cnki.jhmu.20180327.009. 强红梅, 唐军伟, 赵荣, 等. 保肝降脂汤辅助治疗对非酒精性脂肪肝病患者肝功能、胰岛素敏感性的影响[J]. 海南医学院学报, 2018, 24( 6): 707- 710. DOI: 10.13210/j.cnki.jhmu.20180327.009.
[19]	LI XH, CHEN Z, ZHAO L, et al. The relationship between the expression of Chemerin, IRS-1, IRS-2 and p-Akt and insulin resistance in the placenta in pregnant women with GDM[J]. Chin J Diabetes, 2020, 28( 6): 405- 409. DOI: 10.3969/j.issn.1006-6187.2020.06.002. 李晓红, 陈卓, 赵琳, 等. 妊娠期糖尿病患者胎盘组织中趋化素、胰岛素受体底物1、胰岛素受体底物2和磷酸化蛋白激酶B的表达及与胰岛素抵抗的关系[J]. 中国糖尿病杂志, 2020, 28( 6): 405- 409. DOI: 10.3969/j.issn.1006-6187.2020.06.002.
[20]	XING DJ, SUN YH, YU LG, et al. Changes of serum Chemerin level in patients with nonalcoholic fatty liver disease and its relationship with insulin resistance and inflammation[J]. Mod Med J China, 2021, 23( 8): 23- 26. DOI: 10.3969/j.issn.1672-9463.2021.08.006. 邢冬杰, 孙英红, 于龙广, 等. 非酒精性脂肪性肝病患者血清趋化素水平变化及其与胰岛素抵抗、炎症的关系研究[J]. 中国现代医药杂志, 2021, 23( 8): 23- 26. DOI: 10.3969/j.issn.1672-9463.2021.08.006.
[21]	WEI Y, ZHANG JC, LI XJ, et al. Research progress of traditional Chinese medicine on alleviating insulin resistance based on classical insulin conduction and inflammatory signal pathway[J]. Mod Tradit Chin Med Mater Med World Sci Technol, 2022, 24( 5): 2026- 2034. 魏颖, 张嘉诚, 李晓娟, 等. 基于经典胰岛素传导及炎症信号通路的相互作用中药改善胰岛素抵抗作用研究进展[J]. 世界科学技术-中医药现代化, 2022, 24( 5): 2026- 2034.
[22]	LI HX, WEI J, HA XQ. Current research status of chemokines and metabolic diseases[J]. Chin Med Biotechnol, 2020, 15( 5): 508- 511. DOI: 10.3969/j.issn.1673-713X.2020.05.012. 李海霞, 魏静, 哈小琴. 趋化素与代谢性疾病的研究现状[J]. 中国医药生物技术, 2020, 15( 5): 508- 511. DOI: 10.3969/j.issn.1673-713X.2020.05.012.
[23]	WU Z, HU XB, CAO ZH. The role of oxidative stress in pancreatic β cells and type 1 diabetes mellitus[J]. Prog Microbiol Immunol, 2019, 47( 6): 87- 90. DOI: 10.13309/j.cnki.pmi.2019.06.016. 吴颛, 胡小波, 曹朝晖. 胰岛β细胞氧化应激反应及其在1型糖尿病中的作用[J]. 微生物学免疫学进展, 2019, 47( 6): 87- 90. DOI: 10.13309/j.cnki.pmi.2019.06.016.
[24]	HUANG HC, ZHANG Z, ZHANG XZ, et al. Sinapine thiocyanate inhibits hyperlipidemia, hyperglycemia, atherosclerosis and hepatocellular steatosis in IR mice[J]. Chin J Pathophysiol, 2018, 34( 1): 1- 8. DOI: 10.3969/j.issn.1000-4718.2018.01.001. 黄涵柽, 张祝, 张希洲, 等. 芥子碱硫氰酸盐抑制IR小鼠血脂血糖升高、动脉粥样硬化及肝细胞脂肪变性[J]. 中国病理生理杂志, 2018, 34( 1): 1- 8. DOI: 10.3969/j.issn.1000-4718.2018.01.001.
[25]	LI XX, ZHU QL, WANG WS, et al. Elevated chemerin induces insulin resistance in human granulosa-lutein cells from polycystic ovary syndrome patients[J]. FASEB J, 2019, 33( 10): 11303- 11313. DOI: 10.1096/fj.201802829R.
[26]	CIGNARELLI A, GENCHI VA, PERRINI S, et al. Insulin and insulin receptors in adipose tissue development[J]. Int J Mol Sci, 2019, 20( 3): 759. DOI: 10.3390/ijms20030759.
[27]	JIA J, YU F, XIONG Y, et al. Chemerin enhances the adhesion and migration of human endothelial progenitor cells and increases lipid accumulation in mice with atherosclerosis[J]. Lipids Health Dis, 2020, 19( 1): 207. DOI: 10.1186/s12944-020-01378-5.
[28]	WU HY, YANG YF. Research progress on the relationship between free fatty acids and insulin resistance[J]. J Liaoning Univ Tradit Chin Med, 2023, 25( 3): 147- 151. DOI: 10.13194/j.issn.1673-842x.2023.03.029. 吴海燕, 杨宇峰. 游离脂肪酸和胰岛素抵抗相关性研究进展[J]. 辽宁中医药大学学报, 2023, 25( 3): 147- 151. DOI: 10.13194/j.issn.1673-842x.2023.03.029.
[29]	ZHU L, HUANG JF, WANG Y, et al. Chemerin causes lipid metabolic imbalance and induces passive lipid accumulation in human hepatoma cell line via the receptor GPR1[J]. Life Sci, 2021, 278: 119530. DOI: 10.1016/j.lfs.2021.119530.
[30]	LI HL, DONG LL, YANG XH, et al. Relationship of peripheral blood Chemerin with glucose and lipid metabolism, visceral fat, oxidative stress and inflammatory indexes in diabetic patients with MAFLD disease[J]. J Hebei Med Univ, 2022, 43( 3): 275- 279, 294. DOI: 10.3969/j.issn.1007-3205.2022.03.006. 李海玲, 董陆玲, 杨秀红, 等. 糖尿病合并MAFLD患者外周血Chemerin与糖脂代谢、内脏脂肪、氧化应激及炎症指标的关系[J]. 河北医科大学学报, 2022, 43( 3): 275- 279, 294. DOI: 10.3969/j.issn.1007-3205.2022.03.006.
[31]	SERAFIN DS, ALLYN B, SASSANO MF, et al. Chemerin-activated functions of CMKLR1 are regulated by G protein-coupled receptor kinase 6(GRK6) and β-arrestin 2 in inflammatory macrophages[J]. Mol Immunol, 2019, 106: 12- 21. DOI: 10.1016/j.molimm.2018.12.016.
[32]	KARAMFILOVA V, NEDEVA I, ASSYOV Y, et al. Chemerin in obese patients with nonalcoholic fatty liver disease with or without prediabetes[J]. CR Acad Bulg Sci, 2024, 77( 1): 127- 136.
[33]	YANG YM, WANG X, MA J. Research progress on the role of M1/M2 macrophages in hepatic fibrosis[J]. Med J Chin PLA, 2024, 49( 6): 726- 732. DOI: 10.11855/j.issn.0577-7402.1239.2024.0124. 杨钰萌, 王新, 麻婧. M1/M2型巨噬细胞在肝纤维化中的作用研究进展[J]. 解放军医学杂志, 2024, 49( 6): 726- 732. DOI: 10.11855/j.issn.0577-7402.1239.2024.0124.
[34]	WU MB, ZHANG WF, GONG JP, et al. Wortmannin inhibits the activity of NLRP3 in Kupffer cells through the Chemerin/CMKLR1 pathway and relieves nonalcoholic fatty liver in mice[J]. Chongqing Med, 2018, 47( 17): 2279- 2284. DOI: 10.3969/j.issn.1671-8348.2018.17.007. 吴明兵, 张文锋, 龚建平, 等. 渥曼青霉素通过Chemerin/CMKLR1途径抑制Kupffer细胞NLRP3的活性缓解小鼠非酒精性脂肪肝[J]. 重庆医学, 2018, 47( 17): 2279- 2284. DOI: 10.3969/j.issn.1671-8348.2018.17.007.
[35]	XU J, JIN WL, LI X. A new perspective in the treatment of liver fibrosis: Targeting macrophage metabolism[J]. J Clin Hepatol, 2023, 39( 4): 922- 928. DOI: 10.3969/j.issn.1001-5256.2023.04.027. 许钧, 金卫林, 李汛. 肝纤维化治疗的新视角: 靶向巨噬细胞代谢[J]. 临床肝胆病杂志, 2023, 39( 4): 922- 928. DOI: 10.3969/j.issn.1001-5256.2023.04.027.
[36]	XIANG YL, DAI X, GONG JP. The role of Kupffer cells in the pathogenesis of MAFLD[J]. Clin Res Pract, 2021, 6( 20): 195- 198. DOI: 10.19347/j.cnki.2096-1413.202120061. 向阳林, 代鑫, 龚建平. Kupffer细胞在MAFLD发病机制中的作用[J]. 临床医学研究与实践, 2021, 6( 20): 195- 198. DOI: 10.19347/j.cnki.2096-1413.202120061.
[37]	POHL R, FEDER S, HABERL EM, et al. Chemerin overexpression in the liver protects against inflammation in experimental non-alcoholic steatohepatitis[J]. Biomedicines, 2022, 10( 1): 132. DOI: 10.3390/biomedicines10010132.
[38]	HABERL EM, POHL R, REIN-FISCHBOECK L, et al. Overexpression of hepatocyte chemerin-156 lowers tumor burden in a murine model of diethylnitrosamine-induced hepatocellular carcinoma[J]. Int J Mol Sci, 2019, 21( 1): 252. DOI: 10.3390/ijms21010252.
[39]	WU MQ, YANG QR, XU SM, et al. Role of serum Chemerin and related inflammatory factors in non-alcoholic fatty liver disease[J]. J Med Res, 2021, 50( 12): 60- 63. DOI: 10.11969/j.issn.1673-548X.2021.12.014. 吴明奇, 杨晴柔, 徐素美, 等. 血清趋化素Chemerin及相关炎性细胞因子在非酒精性脂肪性肝病中的作用[J]. 医学研究杂志, 2021, 50( 12): 60- 63. DOI: 10.11969/j.issn.1673-548X.2021.12.014.
[40]	DOU B, MA CY, HOU WX, et al. Effects of Jieduan niwan prescription drug containing serum on oxidative stress injury of L02 cells based on TLR4/NF-‍κB/iNOS pathway[J]. Chin J Inf Tradit Chin Med, 2022, 29( 4): 87- 91. DOI: 10.19879/j.cnki.1005-5304.202110034. 窦博, 马重阳, 侯伟欣, 等. 基于TLR4/NF-κB/iNOS通路的截断逆挽方药物血清对L02细胞氧化应激损伤的影响[J]. 中国中医药信息杂志, 2022, 29( 4): 87- 91. DOI: 10.19879/j.cnki.1005-5304.202110034.
[41]	SPIRK M, ZIMNY S, NEUMANN M, et al. Chemerin-156 is the active isoform in human hepatic stellate cells[J]. Int J Mol Sci, 2020, 21( 20): E7555. DOI: 10.3390/ijms21207555.
[42]	KUKLA M, MAZUR W, BUŁDAK RJ, et al. Potential role of leptin, adiponectin and three novel adipokines--visfatin, chemerin and vaspin--in chronic hepatitis[J]. Mol Med, 2011, 17( 11-12): 1397- 410. DOI: 10.2119/molmed.2010.00105.
[43]	NAGARAJAN SR, PAUL-HENG M, KRYCER JR, et al. Lipid and glucose metabolism in hepatocyte cell lines and primary mouse hepatocytes: A comprehensive resource for in vitro studies of hepatic metabolism[J]. Am J Physiol Endocrinol Metab, 2019, 316( 4): E578- E589. DOI: 10.1152/ajpendo.00365.2018.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1)

Get Citation

PDF

XML

Article Metrics

Article views (114) PDF downloads(16)

Association of the adipokine Chemerin with the development and progression of liver fibrosis

DOI: 10.12449/JCH250125

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Association of the adipokine Chemerin with the development and progression of liver fibrosis

DOI: 10.12449/JCH250125

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content